A multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose ranging study of SL77.0499-10 [alfuzosin] once daily tablets in patients with lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)

Trial Profile

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose ranging study of SL77.0499-10 [alfuzosin] once daily tablets in patients with lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Alfuzosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Mar 2009 Actual end date (Aug 2005) added as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Planned number of patients changed from 440 to 473 as reported by ClinicalTrials.gov.
    • 29 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top